epoetin-alfa and Carbon-Monoxide-Poisoning

The purpose of this study was to evaluate the efficacy of erythropoietin (EPO) for treating patients with carbon monoxide (CO) poisoning. We conducted a randomized, prospective study of 103 patients with CO poisoning in two groups: an EPO group (n = 54; patients received EPO) and a placebo group (n = 49; patients received normal saline). The study endpoints were the functional outcome at day 30 (the Barthel index and neurologic sequelae), National Institutes of Health Stroke Scale (NIHSS) score, and the levels of S-100β. At 18 days, the NIHSS score improved significantly and S-100β levels significantly decreased in patients in the EPO group. At 30 days, patients in the EPO group had a superior Barthel index and fewer patients had delayed neurologic sequelae (DNS). This study demonstrated that early administration of EPO to patients with CO poisoning improved neurological outcomes and reduced the incidence of DNS.

Topics: Adult; Biomarkers; Carbon Monoxide Poisoning; Carboxyhemoglobin; Data Collection; Epoetin Alfa; Erythropoietin; Female; Hematinics; Humans; Male; Nerve Growth Factors; Neuroprotective Agents; Recombinant Proteins; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Treatment Outcome